A mathematical model for the evaluation of amplitude of hemoglobin fluctuations in elderly anemic patients affected by myelodysplastic syndromes: correlation with quality of life and fatigue

Leukemia Research

Volumn 31, Issue 2, 2007, Pages 249-252

  Caocci, Giovanni ^a   Baccoli, Roberto ^b   Ledda, Antonio ^a   Littera, Roberto ^a   La Nasa, Giorgio ^a  

^a PO 'R Binaghi'   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Anemia; Fatigue; Hemoglobin fluctuation; Myelodisplasia; Quality of life

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FATIGUE; FEMALE; HUMAN; MALE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MYELODYSPLASTIC SYNDROME; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ANEMIA; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; FATIGUE; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYELODYSPLASTIC SYNDROMES; QUALITY OF LIFE; QUESTIONNAIRES; SOFTWARE; TREATMENT OUTCOME;

EID: 33845292619     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.05.015     Document Type: Article

References (8)

1. Hellström-Lindberg E., Gulbrandsen N., Lindberg G., Alghren T., Dahl I.M., Dyberal I., et al. A validate decision model for treating the anemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 29 (2005) 1217-1219
2. Servaes P., Verhagen C., and Bleijenberg G. Fatigue in cancer patients during and after treatment. Prevalence, correlates and interventions. Eur J Cancer 38 (2002) 27-43
3. Casadevall N., Durieux P., Dubois S., Hemery F., Lepage E., Quarrè M.C., et al. Health, economic, and quality of life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104 (2004) 321-327
4. Jansen A.J.G., Essink-Bot M.L., Beckers E.A.M., Hop W.C.J., Schippeurus M.R., and Van Rhenen D.J. Quality of life measurements in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 121 (2003) 270-274
5. Oliva E.N., Dimitrov B.D., Benedetto F., D'Angelo A., and Nobile F. Hemoglobin level threshold remodeling and quality of life in myelodysplastic syndrome. Leuk Res 29 (2005) 1217-1219
6. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., et al. For the European Organization for Research and Treatment of Cancer study group on quality of life. The EORTC QLQ-30: a quality of life instrument for use in international trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
7. Thomas M.L. Quality of life and psychosocial adjustment in patients with myelodysplastic syndromes. Leuk Res 22 (1998) s41-s47
8. Rizzo J.D., Lichtin A.E., Woolf S.H., Seidenfeld J., Bennet C.L., Cella D., et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Haematology. J Clin Oncol 20 (2002) 4083-4107